Curcumin Cancer Research Results

CUR, Curcumin: Click to Expand ⟱
Features:
Curcumin is the main active ingredient in Tumeric. Member of the ginger family.Curcumin is a polyphenol extracted from turmeric with anti-inflammatory and antioxidant properties.
- Has iron-chelating, iron-chelating properties. Ferritin. But still known to increase Iron in Cancer cells.
- GSH depletion in cancer cells, exhaustion of the antioxidant defense system. But still raises GSH↑ in normal cells.
- Higher concentrations (5-10 μM) of curcumin induce autophagy and ROS production
- Inhibition of TrxR, shifting the enzyme from an antioxidant to a prooxidant
- Strong inhibitor of Glo-I, , causes depletion of cellular ATP and GSH
- Curcumin has been found to act as an activator of Nrf2, (maybe bad in cancer cells?), hence could be combined with Nrf2 knockdown
-may suppress CSC: suppresses self-renewal and pathways (Wnt/Notch/Hedgehog).
Clinical studies testing curcumin in cancer patients have used a range of dosages, often between 500 mg and 8 g per day; however, many studies note that doses on the lower end may not achieve sufficient plasma concentrations for a therapeutic anticancer effect in humans.
• Formulations designed to improve curcumin absorption (like curcumin combined with piperine, nanoparticle formulations, or liposomal curcumin) are often employed in clinical trials to enhance its bioavailability.

-Note half-life 6 hrs.
BioAv is poor, use piperine or other enhancers
Pathways:
- induce ROS production at high concentration. Lowers ROS at lower concentrations
curcumin can act as a pro-oxidant when blue light is applied
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓
- Lowers AntiOxidant defense in Cancer Cells: GSH↓ Catalase↓ HO1↓ GPx↓
but conversely is known as a NRF2↑ activator in cancer
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, uPA↓, VEGF↓, NF-κB↓, CXCR4↓, SDF1↓, TGF-β↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMT1↓, DNMT3A↓, EZH2↓, P53↑, HSP↓, Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, ERK↓, EMT↓, TOP1↓, TET1↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, HK2↓, ECAR↓, OXPHOS↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, CK2↓, Hh↓, GLi1↓, CD133↓, CD24↓, β-catenin↓, n-myc↓, sox2↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK↓, ERK↓, JNK, TrxR**,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 NF-κB signaling ↓ NF-κB activation ↓ inflammatory NF-κB tone Driver Suppression of survival and inflammatory transcription NF-κB is a primary, repeatedly validated curcumin target explaining pleiotropic downstream effects
2 STAT3 signaling ↓ STAT3 phosphorylation / activity ↔ or mild suppression Driver Loss of pro-survival and proliferative signaling STAT3 inhibition contributes to growth arrest, apoptosis sensitization, and reduced cytokine signaling in tumors
3 Reactive oxygen species (ROS) ↑ ROS (dose- & context-dependent) ↓ ROS / buffered Conditional Driver Biphasic redox modulation Curcumin can act as a pro-oxidant in cancer cells with high basal stress while acting antioxidant in normal cells
4 Mitochondrial integrity / intrinsic apoptosis ↓ ΔΨm; ↑ caspase activation ↔ preserved Driver Execution of intrinsic apoptosis Mitochondrial dysfunction and caspase activation occur downstream of NF-κB/STAT3 and ROS effects
5 PI3K → AKT → mTOR axis ↓ AKT / ↓ mTOR ↔ or adaptive suppression Secondary Reduced growth and anabolic signaling AKT/mTOR inhibition contributes to growth suppression and autophagy induction in cancer cells
6 Autophagy ↑ autophagy (protective or pro-death) ↑ adaptive autophagy Secondary Stress adaptation vs cell death Autophagy may be cytoprotective or cooperate with apoptosis depending on context and dose
7 HIF-1α / VEGF hypoxia–angiogenesis axis ↓ HIF-1α; ↓ VEGF ↔ minimal effect Secondary Anti-angiogenic pressure Suppression of hypoxia-driven transcription limits angiogenesis and tumor adaptation
8 Cell cycle regulation ↑ G2/M or G1 arrest ↔ largely spared Phenotypic Cytostatic growth control Cell-cycle arrest reflects upstream signaling and epigenetic effects rather than direct CDK inhibition
9 Migration / invasion (EMT, MMP axis) ↓ migration & invasion ↔ Phenotypic Anti-metastatic phenotype Reduced EMT markers and protease activity limit invasive behavior
10 Epigenetic regulation (p300/CBP HAT activity) ↓ histone acetylation ↔ modest Secondary Transcriptional reprogramming Curcumin modulates chromatin via HAT inhibition rather than classic HDAC inhibition


Scientific Papers found: Click to Expand⟱
432- CUR,    Curcumin-Induced Global Profiling of Transcriptomes in Small Cell Lung Cancer Cells
- in-vitro, Lung, H446
Bcl-2↓, cycF↓, LOX1↓, VEGF↓, MRGPRF↓, BAX↑, Cyt‑c↑, miR-548ah-5p↑,
151- CUR,    Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP
AR↓, PSA↓, Dose↑,
152- CUR,    Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer
- in-vivo, Pca, NA
β-catenin/ZEB1↓, AR↓, STAT3↓, p‑Akt↓, Mcl-1↓, Bcl-xL↓, cl‑PARP↑, miR-21↓, miR-205↑, TumCG↓, TumCP↓, TumCI↓, angioG↓, TumMeta↓,
153- CUR,    Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo
- in-vivo, Pca, C4-2B
PSA↓, TGF-β↓, BMPs↑, TumMeta↓,
154- CUR,    Curcumin inhibits expression of inhibitor of DNA binding 1 in PC3 cells and xenografts
- vitro+vivo, Pca, PC3
Id1↓, TumCG↓,
155- CUR,    Osteopontin and MMP9: Associations with VEGF Expression/Secretion and Angiogenesis in PC3 Prostate Cancer Cells
- in-vitro, Pca, PC3
p‑ERK↓, VEGF↓, angioG↓, MMP2↓, MMP9↓, angioS↑,
157- CUR,    Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
cJun↓, AR↓,
121- CUR,    Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study
- in-vivo, Pca, NA
CTC↓,
10- CUR,    Curcumin Suppresses Lung Cancer Stem Cells via Inhibiting Wnt/β-catenin and Sonic Hedgehog Pathways
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
HH↓, Wnt/(β-catenin)↓, Shh↓, Smo↓, Gli1↝, GLI2↝, CSCs↓, CD133↓, CSCsMark↓,
11- CUR,    Curcumin inhibits hypoxia-induced epithelial‑mesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway
- in-vitro, PC, PANC1
HH↓, Shh↓, Smo↓, Gli1↓, N-cadherin↓, E-cadherin↑, Vim↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓, chemoPv↑,
12- CUR,    Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells
- in-vitro, MB, DAOY
HH↓, Shh↓, Gli1↓, PTCH1↓, cMyc↓, n-MYC↓, cycD1/CCND1↓, Bcl-2↓, NF-kB↓, Akt↓, β-catenin/ZEB1↓, survivin↓, Apoptosis↑, ChemoSen↑, RadioS↑, eff↑,
13- CUR,    Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action
- Review, BC, NA
P53↑, DR5↑, JNK↑, NRF2↑, PPARγ↑, HER2/EBBR2↓, IR↓, ER(estro)↓, Fas↑, PDGF↓, TGF-β↓, FGF↓, EGFR↓, JAK↓, PAK↓, MAPK↓, ATPase↓, COX2↓, MMPs↓, IL1↓, IL2↓, IL5↓, IL6↓, IL8↓, IL12↓, IL18↓, NF-kB↓, NOTCH1↓, STAT1↓, STAT4↓, STAT5↓, STAT3↓,
14- CUR,    Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway
- vitro+vivo, Pca, PC3
PI3K/mTOR/ETS2↓, MDM2↓, P21↑, Apoptosis↑, TumCP↓, eff↑, RadioS↑,
15- CUR,  UA,    Effects of curcumin and ursolic acid in prostate cancer: A systematic review
- Review, Pca, NA
NF-kB↝, Akt↝, AR↝, Apoptosis↝, Bcl-2↝, Casp3↝, BAX↝, P21↝, ROS↝, Bcl-xL↝, JNK↝, MMP2↝, P53↝, PSA↝, VEGF↝, COX2↝, cycD1/CCND1↝, EGFR↝, IL6↝, β-catenin/ZEB1↝, mTOR↝, NRF2↝, AP-1↝, Cyt‑c↝, PI3K↝, PTEN↝, Cyc↝, TNF-α↝,
117- CUR,    Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells
- in-vivo, Pca, RM-1 - in-vivo, Pca, DU145
ROS↑, tumCV↓, Apoptosis↑, TumCCA↑, Ca+2↑, eff↓, ER Stress↑,
118- CUR,    Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
ROS↑, Bcl-2↓, PARP↑, cDC2↓, CycB/CCNB1↓, MDM2↓, eff↓, eIF2α↑, ATF4↑, CHOP↑, ER Stress↑, TumCCA↑,
120- CUR,    A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation
- Human, Pca, NA
PSA↓, Dose↝,
146- CUR,  EGCG,    Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
P21↑, TumCCA↑, TumCP↓, BioAv↓,
122- CUR,  isoFl,    Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen
- Human, Pca, LNCaP
PSA↓, AR↓,
123- CUR,    Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells
- in-vitro, Colon, LoVo - in-vitro, Colon, COLO205 - in-vitro, Pca, PC3 - in-vitro, Pca, 22Rv1
NF-kB↓, ATF3↑, HO-1↑, Wnt↓, Akt↓, mTOR↓, PTEN↑, Apoptosis↑, TGF-β↓, PPARγ↑,
124- CUR,    Curcumin-Gene Expression Response in Hormone Dependent and Independent Metastatic Prostate Cancer Cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, C4-2B
TGF-β↓, Wnt↓, PI3k/Akt/mTOR↓, NF-kB↓, PTEN↑, Apoptosis↑, TumCCA↑,
125- CUR,    Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway
- in-vitro, adrenal, H295R
CYP17A1↓, CYP19↓, *Nrf1↑, *NF-kB↓, angioG↓, Apoptosis↑, AR↓, toxicity↓, BioAv↑,
126- CUR,    Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, PC3 - in-vitro, Pca, DU145
miR-34a↑, β-catenin/ZEB1↓, cMyc↓, P21↑, cycD1/CCND1↓, PCNA↓, TumCG↓,
127- CUR,    The chromatin remodeling protein BRG1 links ELOVL3 trans-activation to prostate cancer metastasis
- in-vitro, Pca, DU145
Elvol3↓, p300↓,
128- CUR,  RES,    Evaluation of biophysical as well as biochemical potential of curcumin and resveratrol during prostate cancer
- in-vivo, Pca, NA
lipid-P↓, chemoPv↑, GSH↑, SOD↑, GSTs↑, glucose↓,
129- CUR,    Curcumin suppressed the prostate cancer by inhibiting JNK pathways via epigenetic regulation
- vitro+vivo, Pca, LNCaP
JNK↓, H3K4↓, TumCG↓, Apoptosis↑, eff↑,
414- CUR,    Transcriptome Investigation and In Vitro Verification of Curcumin-Induced HO-1 as a Feature of Ferroptosis in Breast Cancer Cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
Ferroptosis↑, Iron↑, ROS↑, lipid-P↑, MDA↑, GSH↓, HO-1↑, NRF2↑, GPx↓, ROS↑, Iron↑, GPx4↓, HSP70/HSPA5↑, ATFs↑, CHOP↑, MDA↑, FTL↑, FTH1↑, BACH1↑, REL↑, USF1↑, NFE2L2↑,
182- CUR,  RES,  GI,    Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, LAPC-4
p38↓, MKP5↑, TNF-α↓, COX2↓, NF-kB↓,
158- CUR,    Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis
- vitro+vivo, Pca, LNCaP - in-vitro, Pca, PC3
MMP9↓, Matr↓, Inflam↓, antiOx↓, NF-kB↓, COX2↓, iNOS↓, TumCMig↓, TumCI↓,
404- CUR,    Curcumin induces ferroptosis in non-small-cell lung cancer via activating autophagy
- vitro+vivo, Lung, A549 - vitro+vivo, Lung, H1299
TumAuto↑, TumCG↓, TumCP↓, Iron↑, GSH↓, lipid-P↑, GPx↓, mtDam↑, autolysosome↑, Beclin-1↑, LC3s↑, p62↓, Ferroptosis↑,
405- CUR,  5-FU,    Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis
- vitro+vivo, CRC, HCT116
Apoptosis↑, TumCMig↓, NRF2↑, ROS↑, MET↑, miR-34a↑,
406- CUR,    Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2
- in-vitro, BC, MCF-7 - in-vitro, Hepat, HepG2
GSH↓, Apoptosis↑, Bcl-2↓, cMyc↓,
407- CUR,    Curcumin inhibited growth of human melanoma A375 cells via inciting oxidative stress
- in-vitro, Melanoma, A375
Apoptosis↑, ROS↑, GSH↓, MMP↓,
408- CUR,    Cytotoxic, chemosensitizing and radiosensitizing effects of curcumin based on thioredoxin system inhibition in breast cancer cells: 2D vs. 3D cell culture system
- in-vitro, BC, MCF-7
Trx1↓,
409- CUR,    Curcumin Inhibits Glyoxalase 1—A Possible Link to Its Anti-Inflammatory and Anti-Tumor Activity
- in-vitro, Pca, PC3 - in-vitro, BC, MDA-MB-231
GLO-I↓, GSH↓, ATP↓,
410- CUR,    Nrf2 depletion enhanced curcumin therapy effect in gastric cancer by inducing the excessive accumulation of ROS
- vitro+vivo, GC, AGS - vitro+vivo, GC, HGC27
ROS↑, NRF2↑,
411- CUR,    Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog/Gli1 signaling pathway
- in-vitro, BC, MDA-MB-231
HH↓, EMT↓, Gli1↓,
412- CUR,    Curcumin and Its New Derivatives: Correlation between Cytotoxicity against Breast Cancer Cell Lines, Degradation of PTP1B Phosphatase and ROS Generation
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
ROS↑, PTP1B↓,
413- CUR,    Curcumin attenuates lncRNA H19-induced epithelial-mesenchymal transition in tamoxifen-resistant breast cancer cells
- in-vitro, BC, MCF-7
N-cadherin↓, E-cadherin↑, H19↓,
183- CUR,    Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
AR↓, AP-1↓, NF-kB↓, CBP↓,
415- CUR,    Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis
- vitro+vivo, BC, MDA-MB-231
PSMB5↓, CT-I↓, miR-142-3p↑, EP300↓,
417- CUR,    Curcumin inhibits the growth of triple‐negative breast cancer cells by silencing EZH2 and restoring DLC1 expression
- vitro+vivo, BC, MCF-7 - vitro+vivo, BC, MDA-MB-231 - vitro+vivo, BC, MDA-MB-468
EZH2↓, DLC1↑, cycA1/CCNA1↓, CDK1↓, Bcl-2↓, Casp9↑, DLC1↑,
420- CUR,    Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
Vim↓, Fibronectin↓, β-catenin/ZEB1↓, E-cadherin↓, CD44↑, CD24↓, OCT4↓, Nanog↓, SOX2↓,
422- CUR,    Curcumin induces re-expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines
- in-vitro, BC, HCC-38 - in-vitro, BC, T47D
BRCA1↑, TET1↑, DNMT3A↑, DNMT1↓, SNCG↓, miR-29b↓, miR-29b↑,
423- CUR,    Inhibition of TLR4/TRIF/IRF3 Signaling Pathway by Curcumin in Breast Cancer Cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
TLR4↓, IRF3↓, IFN-γ↓, TRIF↓,
424- CUR,    Curcumin inhibits autocrine growth hormone-mediated invasion and metastasis by targeting NF-κB signaling and polyamine metabolism in breast cancer cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
Src↓, p‑STAT1↓, p‑Akt↓, p‑p44↓, p‑p42↓, RAS↓, Raf↓, Vim↓, β-catenin/ZEB1↓, P53↓, Bcl-2↓, Mcl-1↓, PIAS-3↑, SOCS-3↑, SOCS1↑, ROS↑, NF-kB↓, PAO↑, SSAT↑, P21↑, Bak↑,
425- CUR,    Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells
- in-vitro, BC, T47D - in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
CDC25↓, cDC2↓, P21↑, p‑Akt↓, p‑mTOR↓, Bcl-2↓, BAX↑, Casp3↑,
426- CUR,    Use of cancer chemopreventive phytochemicals as antineoplastic agents
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, CAL51
Bcl-2↓, ROS↑, BAX↑, RAD51↑, γH2AX↑,
427- CUR,    Curcumin suppresses the malignancy of non-small cell lung cancer by modulating the circ-PRKCA/miR-384/ITGB1 pathway
- in-vitro, Lung, H1299 - in-vitro, Lung, H460 - vitro+vivo, Lung, A549
ITGB1↓, circ-PRKCA↓, miR-384↑,
429- CUR,    TAp63α Is Involved in Tobacco Smoke-Induced Lung Cancer EMT and the Anti-cancer Activity of Curcumin via miR-19 Transcriptional Suppression
- in-vitro, Lung, H1299 - in-vitro, Lung, A549
TAp63α↑, E-cadherin↑, ZO-1↑, Vim↓, N-cadherin↓, miR-19b↓,

Showing Research Papers: 201 to 250 of 293
Prev Page 5 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 293

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

H3K4↓, 1,  

Redox & Oxidative Stress ⓘ

antiOx↓, 1,   ATF3↑, 1,   Ferroptosis↑, 2,   GPx↓, 2,   GPx4↓, 1,   GSH↓, 5,   GSH↑, 1,   GSTs↑, 1,   HO-1↑, 2,   Iron↑, 3,   lipid-P↓, 1,   lipid-P↑, 2,   MDA↑, 2,   NFE2L2↑, 1,   NRF2↑, 4,   NRF2↝, 1,   PAO↑, 1,   ROS↑, 10,   ROS↝, 1,   SOD↑, 1,   Trx1↓, 1,  

Metal & Cofactor Biology ⓘ

FTH1↑, 1,   FTL↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   CDC25↓, 1,   MKP5↑, 1,   MMP↓, 1,   mtDam↑, 1,   p‑p42↓, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 3,   Elvol3↓, 1,   GLO-I↓, 1,   glucose↓, 1,   IR↓, 1,   PI3k/Akt/mTOR↓, 1,   PI3K/mTOR/ETS2↓, 1,   PPARγ↑, 2,   PSMB5↓, 1,   SSAT↑, 1,  

Cell Death ⓘ

Akt↓, 2,   Akt↝, 1,   p‑Akt↓, 3,   Apoptosis↑, 10,   Apoptosis↝, 1,   Bak↑, 1,   BAX↑, 3,   BAX↝, 1,   Bcl-2↓, 8,   Bcl-2↝, 1,   Bcl-xL↓, 1,   Bcl-xL↝, 1,   Casp3↑, 1,   Casp3↝, 1,   Casp9↑, 1,   CBP↓, 1,   Cyt‑c↑, 1,   Cyt‑c↝, 1,   DR5↑, 1,   Fas↑, 1,   Ferroptosis↑, 2,   iNOS↓, 1,   JNK↓, 1,   JNK↑, 1,   JNK↝, 1,   MAPK↓, 1,   Mcl-1↓, 2,   MDM2↓, 2,   miR-548ah-5p↑, 1,   p38↓, 1,   survivin↓, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,   PAK↓, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   EZH2↓, 1,   H19↓, 1,   Matr↓, 1,   miR-205↑, 1,   miR-21↓, 1,   tumCV↓, 1,   USF1↑, 1,  

Protein Folding & ER Stress ⓘ

ATFs↑, 1,   CHOP↑, 2,   eIF2α↑, 1,   ER Stress↑, 2,   HSP70/HSPA5↑, 1,  

Autophagy & Lysosomes ⓘ

autolysosome↑, 1,   Beclin-1↑, 1,   LC3s↑, 1,   p62↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

BRCA1↑, 1,   DNMT1↓, 1,   DNMT3A↑, 1,   P53↓, 1,   P53↑, 1,   P53↝, 1,   PARP↑, 1,   cl‑PARP↑, 1,   PCNA↓, 1,   RAD51↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   Cyc↝, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   cycD1/CCND1↝, 1,   cycF↓, 1,   P21↑, 5,   P21↝, 1,   TAp63α↑, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD24↓, 1,   CD44↑, 1,   cDC2↓, 2,   CSCs↓, 1,   CSCsMark↓, 1,   EMT↓, 2,   EP300↓, 1,   p‑ERK↓, 1,   FGF↓, 1,   Gli1↓, 3,   Gli1↝, 1,   HH↓, 4,   Id1↓, 1,   miR-142-3p↑, 1,   miR-34a↑, 2,   mTOR↓, 1,   mTOR↝, 1,   p‑mTOR↓, 1,   n-MYC↓, 1,   Nanog↓, 1,   NOTCH1↓, 1,   OCT4↓, 1,   p300↓, 1,   PI3K↝, 1,   PIAS-3↑, 1,   PTCH1↓, 1,   PTEN↑, 2,   PTEN↝, 1,   RAS↓, 1,   Shh↓, 3,   Smo↓, 2,   SOX2↓, 1,   Src↓, 1,   STAT1↓, 1,   p‑STAT1↓, 1,   STAT3↓, 2,   STAT4↓, 1,   STAT5↓, 1,   TumCG↓, 5,   Wnt↓, 2,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

AP-1↓, 1,   AP-1↝, 1,   ATPase↓, 1,   BACH1↑, 1,   Ca+2↑, 1,   circ-PRKCA↓, 1,   DLC1↑, 2,   E-cadherin↓, 1,   E-cadherin↑, 3,   Fibronectin↓, 1,   GLI2↝, 1,   ITGB1↓, 1,   MET↑, 1,   miR-19b↓, 1,   miR-29b↓, 1,   miR-29b↑, 1,   miR-384↑, 1,   MMP2↓, 1,   MMP2↝, 1,   MMP9↓, 2,   MMPs↓, 1,   MRGPRF↓, 1,   N-cadherin↓, 3,   p‑p44↓, 1,   PDGF↓, 1,   PTP1B↓, 1,   TET1↑, 1,   TGF-β↓, 4,   TumCI↓, 3,   TumCMig↓, 3,   TumCP↓, 5,   TumMeta↓, 2,   Vim↓, 4,   ZO-1↑, 1,   β-catenin/ZEB1↓, 5,   β-catenin/ZEB1↝, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 3,   angioS↑, 1,   ATF4↑, 1,   EGFR↓, 1,   EGFR↝, 1,   LOX1↓, 1,   REL↑, 1,   VEGF↓, 2,   VEGF↝, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   COX2↝, 1,   IFN-γ↓, 1,   IL1↓, 1,   IL12↓, 1,   IL18↓, 1,   IL2↓, 1,   IL5↓, 1,   IL6↓, 1,   IL6↝, 1,   IL8↓, 1,   Inflam↓, 1,   JAK↓, 1,   NF-kB↓, 8,   NF-kB↝, 1,   PSA↓, 4,   PSA↝, 1,   SOCS-3↑, 1,   SOCS1↑, 1,   TLR4↓, 1,   TNF-α↓, 1,   TNF-α↝, 1,   TRIF↓, 1,  

Protein Aggregation ⓘ

SNCG↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 6,   AR↝, 1,   CYP19↓, 1,   ER(estro)↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 1,   ChemoSen↑, 1,   CT-I↓, 1,   CYP17A1↓, 1,   Dose↑, 1,   Dose↝, 1,   eff↓, 2,   eff↑, 3,   RadioS↑, 2,  

Clinical Biomarkers ⓘ

AR↓, 6,   AR↝, 1,   BMPs↑, 1,   BRCA1↑, 1,   CTC↓, 1,   EGFR↓, 1,   EGFR↝, 1,   EZH2↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 1,   IL6↝, 1,   PSA↓, 4,   PSA↝, 1,  

Functional Outcomes ⓘ

chemoPv↑, 2,   toxicity↓, 1,  

Infection & Microbiome ⓘ

IRF3↓, 1,  
Total Targets: 255

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

Nrf1↑, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,  
Total Targets: 2

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:65  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page